Skip to main content

Table 4 Logistic regression models and diagnostic utility measures to identify individuals with ALPL variants

From: Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia

 

Variables included

B

Odds ratio (95% CI)

P value

Diagnostic utility measures

Model 1:

ALP < 25

ALP: − 1.62

0.2 (0.05–0.54)

 < 0.01

S: 57%; Sp: 85%; PPV: 80%; NPV: 66%; +LR: 3.99; −LR:0.5; AC: 71%

C: − 0.72

0.48 (0.18–0.99)

0.06

Model 2:

ALP < 25 + PEA > 30

ALP: − 1.82

0.16 (0.04–0.54)

 < 0.01

S: 71%; Sp: 86%; PPV: 83%; NPV: 75%; +LR: 4.99; −LR: 0.33; AC: 79%

PEA: − 2.43

0.09 (0.02–0.27)

 < 0.001

C: − 1.42

0.24 (0.07–0.63)

 < 0.01

Model 3:

ALP < 25 + PLP > 180

ALP: − 1.38

0.25 (0.05–0.93)

0.02

S: 100%; Sp: 86%; PPV:88%; NPV: 100%; +LR: 6.99; −LR:0; AC: 93%

PLP: − 2.81

0.06 (0.01–0.22)

0.04

C: − 1.51

0.22 (0.04–0.65)

 < 0.001

Model 4:

ALP < 25 + PLP > 180 + PEA > 30

ALP: − 2.3

0.1 (0.01–0.29)

0.02

S: 100%; Sp: 86%; PPV:88%; NPV: 100%; + LR: 6.99; −LR:0; AC: 93%

PLP: − 3.30

0.04 (0.01–0.2)

 < 0.01

PEA: − 2.94

0.05 (0.01–0.25)

 < 0.01

C: − 2.83

0.06 (0.01–0.29)

 < 0.01

Model 5:

ALP < 25 + PLP > 180 + PEA > 30 + C. Pain + Dental ab

ALP: − 2.27

 

0.02

 

PLP: − 3.72

 < 0.01

PEA: − 3.82

 < 0.02

CP:2.34

0.16

DA: − 0.76

0.55

C: − 3.27

 
  1. ALP alkaline phosphatase (IU/L), PLP serum pyridoxal-5′-phosphate (nmol/L), PEA urinary phosphoetanolamine (µmol/g creatinine), C. pain chronic pain, Dental ab dental abnormalities, C constant, S sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value, LR likelihood ratio, AC accuracy